This report provides an overview of global COVID-19 clinical trials extracted from the publisher's Pharma Intelligence Center on April 22, 2021.
The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines vs. therapeutics, and trials impacted by COVID-19.
Scope
Reasons to Buy
The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines vs. therapeutics, and trials impacted by COVID-19.
Scope
- The clinical trials data used for these analyses were extracted from the publisher’s Clinical Trials Database.
- The data included clinical trials that were captured in the database as of April 22, 2021.
- The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and non-COVID-19 trials impacted due to the pandemic. Further analysis was conducted based on multinational vs. single country, clinical trial sites, status, primary endpoint status, terminated trials, phase, sponsor type, and upcoming milestone events.
Reasons to Buy
- Understand the global COVID-19 landscape
- The trends of vaccine COVID-19 clinical trials
- The trends of therapeutic COVID-19 clinical trials
- A closer look at the impact of the pandemic on non-COVID-19 trials
Table of Contents
Executive Summary
List of Tables
List of Figures